A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Apr 2024 According to a Connect Biopharmaceuticals media release, the data from this study were presented at the 2023 Advances in Inflammatory Bowel Diseases Meeting in December 2023.
01 Jun 2023 According to a Connect Biopharma Australia media release, study is conducted over 60 sites in 4 countries.
01 Jun 2023 According to a Connect Biopharma Australia media release, the company plan to submit the full data from the study to a medical congress later this year.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com